XML 53 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2022
Stockholders' Equity Note [Abstract]  
Schedule of ordinary share capital
   December 31, 2022   December 31, 2021 
   Authorized   Issued and
outstanding
   Authorized   Issued and
outstanding
 
   Number of shares 
                     
Ordinary shares with no par value   47,800,000    19,851,833    47,800,000    18,756,570 

 

Schedule of status of options to employees
  

Number

of options

  

Weighted

average

exercise

price

   Aggregate
intrinsic
value
  

Weighted 
average
 
remaining
 

contractual
life (years)

 
                 
Outstanding at beginning of year   2,726,911   $6.25   $2,323    6.44 
Granted   1,124,520   $5.51           
Exercised   (30,206)  $3.60   $21      
Forfeited and expired   (517,879)  $6.57           
                     
Outstanding at end of year   3,303,346   $5.97   $115    6.14 
                     
Exercisable options   2,016,737   $5.81   $115    4.34 
                     
Vested and expected to vest   3,303,346   $5.97   $115    6.14 

 

Schedule of relative fair value of the warrants to purchase Ordinary shares issued
   2022   2021   2020 
             
Dividend yield (%)   0    0    0 
Expected volatility (%)   70.45-92.67    72.97-78.69    74.35-84.77 
Risk-free interest rate (%)   1.81-4.30    0.62-1.32    0.23-1.38 
Expected term (in years)   1.2-6    5-6    5-6 

 

Schedule of share-based compensation expense recognized
  

Year Ended

December 31,

 
   2022   2021   2020 
             
Research and development  $2,081   $2,203   $1,806 
Marketing and business development   383    317    140 
General and administrative   1,843    2,230    2,631 
                
Total share-based compensation expense  $4,307   $4,750   $4,577 

 

Schedule of outstanding options granted
Grant date 

Options
outstanding

as of

December 31,
2022

  

Average
Exercise

price

per share ($)

  

Options

exercisable

as of

December 31,
2022

   Exercisable through
                
October 2013   5,719   $5.06    5,719   October 2023
September 2014   5,719   $5.06    5,719   September 2024
April 2016   5,975   $3.10    5,975   April 2026
December 2016   7,170   $3.93    7,170   December 2026
June 2017   197,722   $4.10    197,722   June 2027
November 2017   17,925   $7.70    17,925   November 2027
August 2019   71,700   $8.18    71,700   August 2029
June 2020   64,530   $6.62    53,724   June 2030
April 2021   62,741   $9.57    62,741   April 2031
August 2021   15,000   $8.13    6,206   August 2031
December 2021   10,000   $6.80    3,300   December 2031
May 2022   65,625   $5.00    32,809   May 2032
November 2022   5,000   $1.05    -   November 2032
                   
    534,826         470,710    

 

Grant date 

Warrants
outstanding

as of

December 31,
2022

  

Average
Exercise

price

per share ($)

  

Warrants
exercisable

as of

December 31,
2022

   Exercisable through
                
August 2019   200,596   $15.95    200,596   August 2023
September 2020   17,925   $16.00    17,925   September 2024
April 2022   155,794   $5.14    155,794   April 2029
July 2022   38,948   $5.14    38,948   April 2029
                   
    413,263         413,263    
Schedule of relative fair value of the warrants to purchase Ordinary shares issued
   July 19,   April 26, 
   2022   2022 
         
Share price ($)   5.12    4.96 
Exercise price ($)   5.14    5.14 
Expected volatility (%)   60.57    60.81 
Adjustment to risk-free interest rate (%)   3.07    2.84 
Dividend yield (%)   
-
    
-
 
Risk-free interest rate (%)   3.11    2.88 
Expected life (in years)   6.72    6.94